Dystoniforeningen: Hyppigere behandling giver bedre livskvalitet
Dystoni
Dystoniforeningen: Hyppigere behandling af dystoni giver bedre livskvalitet
Dystonipatienter har svært ved at få hyppigere behandling på trods af meget hæmmende symptomer.
Sjældne sygdomme
Turning hope into action
Dr. David Fajgenbaum is an immunologist and assistant professor at the Perelman School of Medicine of the University of Pennsylvania. In 2010, he became critically ill with idiopathic multicentric Castleman disease (iMCD).